Insider Purchases: Inside the Buy

Tag: Clinical stage biotech

Biotechnology laboratory where artificial intelligence designs therapeutic antibodies, featuring DNA helices, glowing neural-network interfaces, hair follicle imagery, and an upward stock chart symbolizing Absci's AI-powered drug discovery platform.

🧬 Absci (ABSI): A Director Bought After a 5× Rally. Here's Why the Story May Still Be in Its Early Innings.

When FUNanc1al first highlighted Absci around $4.18, the thesis centered on insider buying and an overlooked AI-biotech platform. Today the stock has nearly tripled, Eli Lilly has invested $100 million, institutions own over 80%, and another director is buying shares. Here's why the story may still be in its early innings.

Read entire article

Tags: ABS-201, ABS201, Absci, AbsciCorp, ABSI, antibody discovery, BiotechStocks, buy or sell ABSI, clinical-stage biotech, Eli Lilly, EliLilly, featured-insiders, FUNanc1al, FunStock, GenerativeAI, genomics, hair loss treatment, HairRegrowth, hub-insiders, insider buying, InsiderBuying, Mary Szela, MarySzela, NASDAQ, precision medicine, risks buying ABSI, SeanMcClain, ShortSqueeze, why buy ABSI
A biotech laboratory where scientists examine glowing neurons and retinal cells while investors, institutional funds, and short sellers watch a countdown clock labeled

🧬 Annexon (ANNX): Insiders Buy Millions While Wall Street Bets Against a Breakthrough

Annexon Biosciences is one of the more intriguing biotech setups of 2026. Directors are buying millions of dollars of stock, institutions own virtually the entire float, short interest is elevated, and multiple clinical and regulatory catalysts loom before year-end. High risk? Absolutely. High potential reward? Possibly.

Read entire article

Tags: annexon, annexon biosciences, AnnexonBiosciences, annx, annx stock, BiotechStocks, buy or sell ANNX, c1q, clinical stage biotech, complement pathway, featured-insiders, funanc1al, FUNanc1al Biotech, FUNanc1al Investing, geographic atrophy, growth stocks, guillain barre syndrome, healthcare investing, healthcare stocks, hub-insiders, insider buying, InsiderBuying, MuneerSatter, Neuroinflammation, Phase3Data, risks buying ANNX, short squeeze, ShortSqueeze, tanruprubart, vonaprument, why buy ANNX